{
    "name": "enfuvirtide",
    "comment": "Rx",
    "other_names": [
        "Fuzeon"
    ],
    "classes": [
        "HIV",
        "Fusion Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/fuzeon-enfuvirtide-342637",
    "pregnancy": {
        "common": [
            "Pregnancy Category: B",
            "Lactation: Unknown whether enfuvirtide is excreted in milk; avoid in breastfeeding women; the CDC advises HIV-infected women not to breast-feed to avoid postnatal transmission of HIV"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Unknown whether enfuvirtide is excreted in milk; avoid in breastfeeding women; the CDC advises HIV-infected women not to breast-feed to avoid postnatal transmission of HIV"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use only in combination with other antiretrovirals",
                "Each injection should be in a different site than the previous one (upper arm, anterior thigh, abdomen)",
                "Monitor for signs and symptoms of pneumonia",
                "Low initial CD4+ T-cell count and high initial viral load",
                "Pulmonary disease, smoking",
                "If pt becomes pregnant, call Antiretroviral Pregnancy Registry 1-800-258-4263",
                "The possibility exists that this drug could result in a false-positive HIV test using (ELISA); use of a confirmatory test (Western blot) is advised",
                "Risk of immune reconstitution syndrome if used in combination with other antiretroviral drugs; patients may develop an inflammatory response to indolent or residual opportunistic infection"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "enfuvirtide, elvitegravir/cobicistat/emtricitabine/tenofovir DF. Other (see comment). Contraindicated. \nComment: Elvitegravir/cobicistat/emtricitabine/tenofovir is a complete regimen for HIV and should not be administered with other antiretrovirals."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betibeglogene autotemcel",
            "description": {
                "common": "enfuvirtide, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabotegravir",
            "description": {
                "common": "enfuvirtide, cabotegravir. Other (see comment). Avoid or Use Alternate Drug. \nComment: Cabotegravir plus rilpivirine is a complete regimen. Coadministration with other antiretroviral medications for treating HIV-1 infection is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, enfuvirtide.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Patients should not take antiretroviral medications for at least 1 month before initiating medications for stem cell mobilization, for the duration of the medications? elimination, and until all cycles of apheresis are completed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abacavir",
            "description": {
                "common": "abacavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "emtricitabine",
            "description": {
                "common": "emtricitabine and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamivudine",
            "description": {
                "common": "enfuvirtide and lamivudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "enfuvirtide and nevirapine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orlistat",
            "description": {
                "common": "orlistat will decrease the level or effect of enfuvirtide by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stavudine",
            "description": {
                "common": "enfuvirtide and stavudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "enfuvirtide and tenofovir DF both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of enfuvirtide by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "enfuvirtide and zidovudine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Difficult to separate from background regimen",
            "percent": "98"
        },
        {
            "name": "Multiple inj site rxn",
            "percent": "96"
        },
        {
            "name": "Pain",
            "percent": "91"
        },
        {
            "name": "discomfort",
            "percent": "90"
        },
        {
            "name": "Erythema",
            "percent": "80"
        },
        {
            "name": "Induration",
            "percent": "65"
        },
        {
            "name": "Nodules and cysts",
            "percent": "52"
        },
        {
            "name": "Pruritis",
            "percent": "31"
        },
        {
            "name": "Ecchymosis",
            "percent": "22"
        },
        {
            "name": "Diarrhea",
            "percent": "20"
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Periph",
            "percent": null
        },
        {
            "name": "neuropathy",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Difficult to separate from background regimen",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Pruritis",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Decreased appetite",
            "percent": null
        },
        {
            "name": "Weight loss",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Herpes simplex",
            "percent": null
        },
        {
            "name": "Influenza",
            "percent": null
        },
        {
            "name": "like illness",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Sinusitis",
            "percent": null
        },
        {
            "name": "Lymphadenopathy",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Unstable angina",
            "percent": null
        },
        {
            "name": "Toxic hepatitis",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "Respiratory distress",
            "percent": null
        },
        {
            "name": "Guillain",
            "percent": null
        },
        {
            "name": "Barre syndrome",
            "percent": null
        },
        {
            "name": "Hypersensitivity rxn",
            "percent": null
        },
        {
            "name": "Primary immune complex reaction",
            "percent": null
        },
        {
            "name": "Suicide attempt",
            "percent": null
        },
        {
            "name": "Cutaneous amyloidosis at the injection site",
            "percent": null
        }
    ]
}